[go: up one dir, main page]

EA200802012A1 - Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением - Google Patents

Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением

Info

Publication number
EA200802012A1
EA200802012A1 EA200802012A EA200802012A EA200802012A1 EA 200802012 A1 EA200802012 A1 EA 200802012A1 EA 200802012 A EA200802012 A EA 200802012A EA 200802012 A EA200802012 A EA 200802012A EA 200802012 A1 EA200802012 A1 EA 200802012A1
Authority
EA
Eurasian Patent Office
Prior art keywords
solution
under pressure
pharmaceutical preparations
active drug
drug substances
Prior art date
Application number
EA200802012A
Other languages
English (en)
Other versions
EA016262B1 (ru
Inventor
Дэвид Эндрю Льюис
Брайан Джон Микин
Гаэтано Брамбилла
Original Assignee
КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38230023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200802012(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. filed Critical КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А.
Publication of EA200802012A1 publication Critical patent/EA200802012A1/ru
Publication of EA016262B1 publication Critical patent/EA016262B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • A61K9/124Aerosols; Foams characterised by the propellant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретение относится к применению препарата в форме раствора для дозирующих ингаляторов под давлением, способных обеспечить доставку терапевтических доз двух или более активных лекарственных веществ в легкое, для изготовления лекарственного средства для предупреждения или лечения тяжелого бронхолегочного заболевания, где все активные лекарственные вещества полностью растворены в препарате, а также два или более активных лекарственных вещества доставляются, по существу, с одинаковым распределением частиц по размерам.
EA200802012A 2006-04-21 2007-04-19 Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением EA016262B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/408,026 US20060257324A1 (en) 2000-05-22 2006-04-21 Pharmaceutical solution formulations for pressurised metered dose inhalers
PCT/EP2007/003420 WO2007121913A2 (en) 2006-04-21 2007-04-19 Pharmaceutical solution formulations for pressurised metered dose inhalers

Publications (2)

Publication Number Publication Date
EA200802012A1 true EA200802012A1 (ru) 2009-04-28
EA016262B1 EA016262B1 (ru) 2012-03-30

Family

ID=38230023

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200802012A EA016262B1 (ru) 2006-04-21 2007-04-19 Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением

Country Status (21)

Country Link
US (4) US20060257324A1 (ru)
EP (1) EP2010190B1 (ru)
JP (1) JP5289306B2 (ru)
KR (1) KR101311662B1 (ru)
CN (4) CN106074359A (ru)
AU (1) AU2007241336C1 (ru)
BR (1) BRPI0709510A2 (ru)
CA (1) CA2649556C (ru)
CY (1) CY1114215T1 (ru)
DK (1) DK2010190T3 (ru)
EA (1) EA016262B1 (ru)
ES (1) ES2424753T3 (ru)
HR (1) HRP20130835T1 (ru)
ME (1) ME02342B (ru)
MX (1) MX2008013460A (ru)
PL (1) PL2010190T3 (ru)
PT (1) PT2010190E (ru)
RS (1) RS52940B (ru)
SI (1) SI2010190T1 (ru)
WO (1) WO2007121913A2 (ru)
ZA (1) ZA200808965B (ru)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
PL207377B1 (pl) * 2001-03-30 2010-12-31 Jagotec Ag Medyczny preparat aerozolowy, sposób wytwarzania medycznego preparatu aerozolowego oraz zastosowanie soli kwasów karboksylowych jako środków pomocniczych w tym preparacie
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
DE602005008946D1 (de) * 2004-05-13 2008-09-25 Chiesi Farma Spa Medizinische aerosolformulierungen mit verbesserter chemischer stabilität
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
CA2615378C (en) * 2005-07-15 2015-02-17 Map Pharmaceuticals, Inc. Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
US20100291221A1 (en) * 2009-05-15 2010-11-18 Robert Owen Cook Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
EP2429297A4 (en) * 2009-05-15 2013-12-25 Map Pharmaceuticals Inc METHOD FOR THE ADMINISTRATION OF DOSE-SAVING QUANTITIES OF FORMOTEROL-FUMARATE BUDESONIDE COMBINATION PARTICLES BY INHALATION
HUE029532T2 (en) 2009-05-29 2017-03-28 Pearl Therapeutics Inc Respiratory delivery of active agents
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
WO2010144628A2 (en) * 2009-06-09 2010-12-16 Elevation Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
GB0918150D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
GB0918149D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
GEP20156311B (en) * 2009-12-23 2015-07-10 Chiesi Farma Spa Combination therapy for copd
CA2785317C (en) 2009-12-23 2018-02-27 Chiesi Farmaceutici S.P.A. Aerosol formulation for copd
CA2785349C (en) * 2009-12-23 2018-07-03 Chiesi Farmaceutici S.P.A. Combination therapy for copd
RU2567040C2 (ru) * 2009-12-23 2015-10-27 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Аэрозольная препаративная форма для лечения по поводу хронического обструктивного легочного заболевания
EP2536412B1 (en) * 2010-02-16 2014-11-12 Teva Branded Pharmaceutical Products R & D, Inc. An inhalable pharmaceutical composition
WO2011136752A1 (en) * 2010-04-26 2011-11-03 Mahmut Bilgic Combined pharmaceutical composition comprising carmoterol and ciclesonide for the treatment of respiratory diseases
WO2011136754A1 (en) * 2010-04-26 2011-11-03 Mahmut Bilgic A medicament developed for the treatment of respiratory diseases
CN102266560A (zh) * 2010-06-04 2011-12-07 北京阜康仁生物制药科技有限公司 一种用于治疗气喘的药物组合物
CN103096897A (zh) * 2010-07-16 2013-05-08 希普拉有限公司 包含r(+)布地奈德和一种或多种支气管扩张剂的药物组合物
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
RU2696582C2 (ru) 2013-03-15 2019-08-05 Перл Терапьютикс, Инк. Способы и системы кондиционирования дисперсных кристаллических материалов
HUE039513T2 (hu) 2013-12-30 2019-01-28 Chiesi Farm Spa Glikopirrónium-bromid és formoterol kombinációját tartalmazó nyomás alatti stabil aeroszol oldatkészítmény
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
GB201515310D0 (en) * 2015-08-27 2015-10-14 Jagotec Ag Pharmaceutical composition
ES2796177T5 (es) 2015-12-04 2024-10-29 Mexichem Fluor Sa De Cv Composición farmacéutica
AU2017328905C1 (en) 2016-09-19 2020-08-06 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
EA201990501A1 (ru) * 2016-09-19 2019-09-30 Мехикем Флуор С.А. Де С.В. Фармацевтическая композиция
MX392213B (es) 2016-09-19 2025-03-21 Mexichem Fluor Sa De Cv Composiciones farmacéuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano.
CA3036628C (en) * 2016-09-19 2021-11-16 Mexichem Fluor S.A. De C.V. Pharmaceutical compositions comprising tiotropium bromide monohydrate and 1,1-difluoroethane
US10792256B2 (en) 2016-09-19 2020-10-06 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
EP3801457A1 (en) 2018-06-04 2021-04-14 Lupin Inc. Stable pharmaceutical compositions for pressurized metered dose inhalers
WO2020152548A1 (en) * 2019-01-24 2020-07-30 Glenmark Pharmaceuticals Limited Stable aerosol inhalation compositions of formoterol
CA3152578A1 (en) * 2019-12-02 2021-06-10 Enrico Zambelli Stainles steel can for pressurised metered dose inhalers
CN120037526A (zh) * 2020-02-20 2025-05-27 奇斯药制品公司 包含缓冲药物制剂的加压定量吸入器
CN111467498A (zh) * 2020-05-14 2020-07-31 王兆霖 药物组合物制剂
TW202228690A (zh) 2020-09-29 2022-08-01 美商艾法瑪實驗室公司 茚達特羅(indacaterol)之液體調配物
GB2614901A (en) 2022-01-21 2023-07-26 Nanopharm Ltd Inhalable formulations

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE128350T1 (de) 1991-12-12 1995-10-15 Glaxo Group Ltd Pharmazeutische aerosolformulierung.
HU0004452D0 (ru) * 1991-12-18 2001-01-29 Astra Ab
US5483953A (en) * 1995-04-08 1996-01-16 The United States Of America As Represented By The Secretary Of The Navy Aerosol dispensing apparatus for dispensing a medicated vapor into the lungs of a patient
US6461591B1 (en) * 1997-02-05 2002-10-08 Jago Research Ag Medical aerosol formulations
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6173047B1 (en) * 1997-08-11 2001-01-09 Dale W. Malik System and method for temporary voicemail service
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
WO2000006121A1 (de) 1998-07-24 2000-02-10 Jago Research Ag Medizinische aerosolformulierungen
CN1150890C (zh) * 1998-08-04 2004-05-26 杰格研究股份公司 药用气溶胶制剂
IT1303788B1 (it) 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
SE9900833D0 (sv) 1999-03-09 1999-03-09 Astra Ab Novel combination
WO2001047493A1 (en) * 1999-12-24 2001-07-05 Glaxo Group Limited Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
IT1317846B1 (it) * 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
SK286694B6 (sk) * 2000-05-22 2009-03-05 Chiesi Farmaceutici S.P.A. Aerosólový farmaceutický prostriedok
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
US6451287B1 (en) * 2000-05-26 2002-09-17 Smithkline Beecham Corporation Fluorinated copolymer surfactants and use thereof in aerosol compositions
FI20002216A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
IL157580A0 (en) * 2001-03-20 2004-03-28 Glaxo Group Ltd Inhalation drug combination
US20030178022A1 (en) * 2001-12-21 2003-09-25 Chiesi Farmaceutici S.P.A. Pressurized metered dose inhaler (PMDI) actuators and medicinal aerosol solution formulation products comprising therse actuators
HUE049426T2 (hu) 2002-03-01 2020-09-28 Chiesi Farm Spa Szuperfinom formoterolkészítmény
EP1415647A1 (en) * 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. "Long-acting beta-2 agonists ultrafine formulations"
EP1340492A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects
EP2319583A1 (en) * 2002-08-29 2011-05-11 Cipla Ltd. Pharmaceutical products and compositions comprising salmeterol, budesonide and ipratropium
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
US7459146B2 (en) * 2003-05-30 2008-12-02 3M Innovative Properties Company Stabilized aerosol dispersions
MXPA06001642A (es) * 2003-08-11 2006-04-28 Glaxo Group Ltd Inhalador farmaceutico de dosis medida y metodos relacionados con el mismo.
US20050287077A1 (en) * 2004-02-10 2005-12-29 James E. Shipley Process for preparing stable SOL of pharmaceutical ingredients and hydrofluorocarbon
EP1595531A1 (en) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
JP2007528409A (ja) 2004-03-09 2007-10-11 アリバ ファーマシューティカルズ, インコーポレイテッド プロテアーゼインヒビターの低用量吸入による慢性閉塞性肺疾患の処置
AU2005293328B2 (en) * 2004-10-12 2010-09-30 Generics (Uk) Limited Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister
BRPI0608087A2 (pt) * 2005-02-15 2009-11-10 Elan Pharma Int Ltd formulações injetáveis e em aerossol de benzodiazepina em nanopartìculas
US10098837B2 (en) * 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD

Also Published As

Publication number Publication date
US20170065518A1 (en) 2017-03-09
KR20080110985A (ko) 2008-12-22
JP5289306B2 (ja) 2013-09-11
US11213485B2 (en) 2022-01-04
US20060257324A1 (en) 2006-11-16
PL2010190T3 (pl) 2013-11-29
CY1114215T1 (el) 2016-08-31
SI2010190T1 (sl) 2013-10-30
BRPI0709510A2 (pt) 2011-07-19
CN101389341A (zh) 2009-03-18
WO2007121913A3 (en) 2008-03-06
EP2010190A2 (en) 2009-01-07
AU2007241336C1 (en) 2023-06-29
CA2649556A1 (en) 2007-11-01
ES2424753T3 (es) 2013-10-08
WO2007121913A2 (en) 2007-11-01
MX2008013460A (es) 2008-10-29
AU2007241336A1 (en) 2007-11-01
CN105963249A (zh) 2016-09-28
CA2649556C (en) 2014-04-15
US10525006B2 (en) 2020-01-07
CN102908308A (zh) 2013-02-06
EA016262B1 (ru) 2012-03-30
HRP20130835T1 (hr) 2013-10-25
EP2010190B1 (en) 2013-06-12
RS52940B (sr) 2014-02-28
DK2010190T3 (da) 2013-08-26
US20200085729A1 (en) 2020-03-19
US20090130026A1 (en) 2009-05-21
JP2009534333A (ja) 2009-09-24
AU2007241336B2 (en) 2012-12-06
CN106074359A (zh) 2016-11-09
ME02342B (me) 2016-06-20
KR101311662B1 (ko) 2013-09-25
PT2010190E (pt) 2013-08-26
ZA200808965B (en) 2009-12-30

Similar Documents

Publication Publication Date Title
EA200802012A1 (ru) Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением
CY1119805T1 (el) Συστημα χορηγησης φαρμακων για τη χορηγηση πτωχως υδατοδιαλυτων φαρμακευτικως ενεργων ουσιων
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
BR0108730A (pt) Sistema, dispositivo e método para administração de uma droga, bocal de um dispositivo de administração de droga, dispositivo para administração de doses unitárias múltiplas de uma droga, métodos para preparação de um sistema de administração de droga e de uma formulação de droga e para tratamento de um paciente que necessita de doses múltiplas de uma droga, formulação de droga e multiparticulados
DE602007010276D1 (de) Trockenpulver-inhaliergerät zur gleichzeitigen verabreichung von mehr als einem medikament
HRP20140592T1 (hr) Poboljšani medicinski pripravci koji sadrže buprenorfin i naltrekson
PL2043637T3 (pl) Sposoby i leki do podawania ibuprofenu
TR201109804A2 (tr) Tek dozlu inhalasyon cihazı.
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
JP2011513437A5 (ru)
SE0402345L (sv) Uppmätt läkemedelsdos
MX2013003523A (es) Composicion farmaceutica de dosis baja.
SE0401612L (sv) Inhalator som använder balja
RU2012108144A (ru) Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами
CY1117596T1 (el) Φαρμακευτικeς συνθeσεις αερολyματος φορμοτερολης και διπροπιονικης βεκλομεθαζονης
SE0303091D0 (sv) Combined doses of tiotropium andfluticasone
BRPI0607172A2 (pt) método para a ministração de pelo menos uma substáncia farmaceuticamente ativa a um paciente, combinação de medicamentos e uso de pelo menos uma substáncia farmaceuticamente ativa para a fabricação de uma combinação de medicamentos
RU2010140888A (ru) Улучшенные противораковые терапии
CN102727515A (zh) 一种治疗脚气的药物制剂
JP2010519274A5 (ru)
EA200801854A1 (ru) Новые композиции
EA201590323A1 (ru) Способ введения активных веществ в головной мозг
RU2021119487A (ru) Комбинированное лекарственное средство, обладающее противовирусным эффектом для профилактики заражения SARS-CoV-2
UA144734U (uk) Спосіб лікування вірусних інфекційних захворювань
TH173838A (th) เครื่องพ่นละอองยาผงแห้ง

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

ND4A Extension of term of a eurasian patent
MF4A Revocation of a eurasian patent as invalid entirely

Designated state(s): RU